In this Health Moonshot Update, we learn about the power of photobiomodulation, a light therapy that promotes healing at the cellular level. From treating seasonal affective disorder to wound healing, light therapy’s applications are expanding. We get updates and insights from Guillaume Blivet of REGEnLIFE, a member of the StartUp Health community who is pioneering research into using photobiomodulation to address Alzheimer’s disease. Learn how their unique approach, targeting both the brain and gut, shows promise in reducing inflammation and improving cellular health. We discuss the science, the promising early results, and the potential of this groundbreaking approach. REGEnLIFE aims to make the therapy accessible not only in hospitals but eventually at home for patients. Highlights 💡 Photobiomodulation: The therapy uses specific red and near-infrared light wavelengths to activate biological functions, especially in the brain, by modulating inflammation and promoting mitochondrial health. 🧠 Focus on Alzheimer’s Disease: REGEnLIFE is working on Alzheimer’s treatment, aiming to improve symptoms and slow disease progression through light therapy. 🏥 Clinical Trials: Their clinical trials show promising results in reducing neuroinflammation and improving symptoms in conditions like Alzheimer’s, multiple sclerosis, and depression. 🏠 Bringing It Home: Currently conducting clinical trials in hospitals, with plans to expand and eventually make the treatment available at home. 🔬 The Brain-Gut Connection: Studies suggest combining light therapy for both the brain and gut leads to better therapeutic outcomes due to the interconnectedness of these organs. ⚙️ Technological Innovation: Challenges in delivering light to the brain are addressed through a specialized helmet that allows the light to penetrate the skull effectively. 🌍 Global Health Perspective: The company operates in the south of France, contributing to a strong health tech ecosystem, with a focus on preventative health and holistic wellness.